Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
Federal Trade Commission
McKesson
Covington
Dow
Medtronic
QuintilesIMS
Moodys

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,841,286

« Back to Dashboard

Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Medina, WA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Sep 26, 2011
Application Number:13/245,705
Claims:1. A formulation package comprising: a) an aztreonam lysinate suitable for inhalation and in dry or lyophilized powder form prepared from .alpha.-aztreonam; and b) a diluent; wherein the aztreonam lysinate in dry or lyophilized powder form and the diluent are stored separately.

2. The formulation package of claim 1, wherein said diluent is a saline solution.

3. The formulation package of claim 2, wherein said diluent is a saline solution containing from 0.09% w/v to 0.9% w/v of sodium chloride.

4. The formulation package of claim 3, wherein said saline solution is a 0.17 mg/mL NaCl solution.

5. The formulation package of claim 4, wherein said saline solution is present in a volume of from 1 to 5 mL.

6. The formulation package of claim 4, wherein said saline solution is present in a volume of 1 mL.

7. The formulation package of claim 1, wherein said aztreonam lysinate in dry or lyophilized powder form prepared from .alpha.-aztreonam comprises from about 1 to about 250 mg aztreonam lysinate.

8. The formulation package of claim 1, wherein said aztreonam lysinate in dry or lyophilized powder form prepared from .alpha.-aztreonam comprises from about 10 to about 150 mg aztreonam lysinate.

9. The formulation package of claim 1, wherein said aztreonam lysinate in dry or lyophilized powder form prepared from .alpha.-aztreonam comprises 75 mg aztreonam and 47 mg lysine.

10. A formulation package comprising: a) aztreonam lysinate suitable for inhalation and in dry or lyophilized powder form comprising 75 mg .alpha.-aztreonam and 47 mg lysine; and b) 1 mL of a 0.17 mg/mL NaCl solution; wherein the aztreonam lysinate in dry or lyophilized powder form and the NaCl solution are stored separately.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fuji
US Army
UBS
Boehringer Ingelheim
Citi
Queensland Health
Accenture
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.